Robert Selfe, DO
Internal Medicine · Grand Rapids, MINPI 1003038605
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $210,905 of the $238,201 with a category attached, or 88.5%. Novo Nordisk accounts for 65.3% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $67,585, more than ten times the $123 reported in 2019. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 388 payments — averaging $613.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$155K
- Dexcom, Inc.$63K
- Tandem Diabetes Care, Inc.$18K
- Medtronic$865
- Lilly USA, LLC$410
- Abbott$243
- plus $531 from 5 others
What the payments were for
- Speaking & faculty fees$210,90589%
- Travel & lodging$16,2517%
- Food & beverage$11,0135%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 229 | $155,497 |
| Dexcom, Inc. | 83 | $63,116 |
| Tandem Diabetes Care, Inc. | 30 | $17,541 |
| Medtronic(2 entities) | 10 | $865 |
| Lilly USA, LLC | 21 | $410 |
| Abbott | 4 | $243 |
| Sequel Med Tech, LLC | 2 | $152 |
| BETA Bionics, Inc. | 1 | $138 |
| Boehringer Ingelheim | 1 | $120 |
| Sanofi-aventis U.S. LLC | 5 | $80 |
| Insulet Corporation | 2 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$77,406
- RYBELSUS$66,430
- DEXCOM G7 GSS (161)$49,248
- t:slim X2 Insulin Pump with Control-IQ$16,746
- DEXCOM STELO GLUCOSE BIOSENSOR$12,892
- DEXCOM G6 TRANSMITTER$12,589
- MINIMED 780G$667
- iLet Bionic Pancreas$414
- FREESTYLE LIBRE 3$158
- TWIIST$146
- Wegovy$125
- JARDIANCE$120
- Minimed 770G System$117
How this compares
$238,201 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 204 | $248,667 |
| TrulicityDulaglutide | 138 | $189,251 |
| OzempicSemaglutide | 115 | $184,265 |
| JardianceEmpagliflozin | 87 | $94,576 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $55,777 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $48,152 |
| Humalog Kwikpen U-100Insulin Lispro | 105 | $42,306 |
| FarxigaDapagliflozin Propanediol | 33 | $38,433 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 203 | $37,051 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $29,049 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 19 | $26,602 |
| JanuviaSitagliptin Phosphate | 20 | $24,894 |
| Novolog FlexpenInsulin Aspart | 59 | $22,119 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $17,201 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $14,798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $410 | $445,276377 claims |
| Novo NordiskOzempic, Novolog | $155,497 | $191,617134 claims |
| Boehringer IngelheimJardiance | $120 | $94,57687 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $80 | $12,64435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Grand Rapids
- Celia EganGrand Rapids$54K
- Jeremy GentileGrand Rapids$44K
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.